BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, July 29, 2026
Breaking News: Best of BioWorld Science: Q2Breaking News: Science fiction realized: BCI tech is hereBreaking News: Science fiction realized: BCI tech is here
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Concept art for H. pylori infection and gastric cancer risk
Biomarkers

SAE1 is up-regulated in gastric cancer and associated with poor outcomes

Feb. 14, 2024
Infection with Helicobacter pylori is a risk factor for the development of gastric cancer. H. pylori initiates a chronic inflammatory response that can lead to the production of excessive radical oxygen species (ROS), which in turn can activate oncogenic signaling pathways leading to gastric cancer development. SUMOylation is a post-translational modification mechanism in cells in response to reactions to stress. A team at The First Affiliated Hospital of Nanchang University hence set out to study the role of SUMO-activating enzyme subunit 1 (SAE1) in gastric cancer, since it is a SUMO-activating effector protein.
Read More
Neurology/Psychiatric

TMEM97 mediates synaptotoxicity as a synaptic binding partner for Aβ

Feb. 14, 2024
Oligomeric amyloid-β (Aβ) peptide causes synaptic dysfunction, accumulates within synapses, and has been associated with synapse loss around plaques in Alzheimer’s disease (AD). However, there is a need to identify synaptic binding partners of Aβ that mediate synaptotoxicity in the brain. A team of investigators from the University of Edinburgh and affiliated organizations aimed to identify synaptic receptors that bind Aβ in human AD.
Read More
Petri dish and capsules
Infection

CARB-X funds research at Harvard on oral antibiotics for resistant bacteria

Feb. 14, 2024
Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), led by Boston University, is awarding $1.2 million to the Andrew G. Myers Research Group at Harvard University to develop a series of enhanced oral antibiotics that directly target a range of antibiotic-resistant bacteria which cause serious lower respiratory tract and skin and soft tissue infections.
Read More
Brain and DNA
Neurology/Psychiatric

PPMD funding supports Kinea’s AAV-mediated midi-dystrophin gene replacement therapy for DMD

Feb. 14, 2024
Parents Project Muscular Dystrophy (PPMD) has provided $500,000 in funding to Kinea Bio Inc. 
Read More
Endocrine/Metabolic

Autologous B-cell therapy WFX-001 corrects systemic α-GAL enzyme deficiency in vivo

Feb. 14, 2024
Walking Fish Therapeutics Inc. presented a new first-in-class autologous B-cell therapy being developed for the treatment of Fabry disease.
Read More
Muscular dystrophy
Neurology/Psychiatric

SAT-3247 improves skeletal muscle function in mouse model of facioscapulohumeral muscular dystrophy

Feb. 14, 2024
Satellos Bioscience Inc. has released promising preliminary data showing SAT-3247 can improve skeletal muscle function in a mouse model of...
Read More
Neuron
Neurology/Psychiatric

GABA-A receptor potentiator KRM-II-81 blocks pain-like behaviors in rats

Feb. 14, 2024
Respirerx Pharmaceuticals Inc.’s lead GABA-A receptor potentiator, KRM-II-81, has advanced to the next level of evaluation within the National...
Read More
Neurology/Psychiatric

VST Bio presents data on novel anti-syndecan-2 antibody

Feb. 14, 2024
It has been shown that vascular endothelial growth factor A (VEGF-A) induces blood-brain barrier disruption and vasogenic edema and it is up-regulated in stroke. When bound to its receptor, VEGF promotes angiogenesis and neuroprotection, in addition to inducing vasogenic edema. VST Bio Ltd. and Yale University have presented data on their monoclonal antibody against syndecan-2, named VST-002, that completely blocks VEGF-driven vasogenic edema while preserving neuroprotective effects.
Read More
Man holding head in pain, brain inset
Neurology/Psychiatric

Degrading damaged mitochondria improves concussion

Feb. 14, 2024
By Mar de Miguel
In repeated concussions, removing damaged mitochondria could prevent the neurodegeneration that occurs when pathology progresses in some patients. The key would be in the role of the p17 protein in restoring mitophagy, according to scientists from the Medical University of South Carolina (MUSC). “Brain injury is an extrinsic disease. It is not idiopathic. When the primary injury occurs, the secure mechanism only relies on an endogenous protection of the brain. If you have a good neuroprotective mechanism, then after the primary injury, basically you don’t see any symptomatic effect,” Onder Albayram told BioWorld.
Read More
Masayo Takahashi, CEO, Vision Care
Ocular

Newco news: Vision Care’s iPS retinal cells primed for global market

Feb. 13, 2024
By Tamra Sami
Vision Care Group CEO Masayo Takahashi led the world's first clinical study of a retinal cell transplant derived from induced pluripotent stem cells (iPS cells) in 2014 when she led the Laboratory for Retinal Regeneration at Japan’s Riken Center for Biosystems Dynamics Research. In 2019, she founded Vision Care and subsequently founded two subsidiary companies dedicated to developing cell and gene therapies.
Read More
Previous 1 2 … 877 878 879 880 881 882 883 884 885 … 18139 18140 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 29, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 28, 2026
  • Illustration of dopamine signaling in the brain

    New schizophrenia targets challenge trial design

    BioWorld
    The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
  • Regulatory actions for July 27, 2026

    BioWorld
    Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Alfasigma,...
  • Other news to note for July 27, 2026

    BioWorld
    Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Abbvie, Genmab, Merck, Par, Thyora.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing